You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrent Endometrial Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Endometrial Cancer Trial (Navtemadlin, Navtemadlin Placebo)

Not yet recruiting
  • Endometrial Cancer
  • (no location specified)
Mar 21, 2023

Endometrial Cancer Trial in Houston (DKN-01, Pembrolizumab)

Not yet recruiting
  • Endometrial Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Feb 27, 2023

Endometrial Cancer Trial in Morristown, Houston (Letrozole, RAD001 (Everolimus))

Active, not recruiting
Has Results
  • Endometrial Cancer
  • Morristown, New Jersey
  • +1 more
Nov 16, 2022

Recurrent Endometrial Cancer, Solid Tumors Trial in Pittsburgh (pembrolizumab, Sitravatinib)

Recruiting
  • Recurrent Endometrial Cancer
  • Solid Tumors
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 12, 2022

Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer Trial in Richmond (Lenvatinib, Pembrolizumab)

Recruiting
  • Endometrial Cancer
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University
Apr 5, 2022

Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer Trial (BKM120, Nabpaclitaxel)

Withdrawn
  • Ovarian Cancer
  • +3 more
  • (no location specified)
Jul 27, 2022

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Endometrial Cancer, Endometrioid Tumor, Cancer Trial in Oklahoma City (nab-sirolimus)

Not yet recruiting
  • Endometrial Cancer
  • +5 more
  • Oklahoma City, Oklahoma
    University Oklahoma Stephenson Cancer Center
Aug 16, 2023

Endometrial Cancer, Endometrial Adenocarcinoma Trial (Cadonilimab, Carboplatin, Cisplatin)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • (no location specified)
Oct 7, 2023

Endometrial Cancer, Recurrent Endometrial Cancer Trial in United States (LY3023414)

Completed
  • Endometrial Cancer
  • Recurrent Endometrial Cancer
  • Basking Ridge, New Jersey
  • +5 more
Sep 13, 2022

Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer Trial (ART0380)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • (no location specified)
Apr 5, 2023

Endometrial Cancer Trial in New Haven (IMGN853)

Recruiting
  • Endometrial Cancer
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 10, 2022

Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in

Recruiting
  • Recurrent Endometrial Adenocarcinoma
  • +8 more
  • Ipilimumab
  • Nivolumab
  • Iowa City, Iowa
  • +9 more
Jan 27, 2023

Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma Trial in Columbus (Lenvatinib Mesylate,

Completed
  • Fallopian Tube Carcinoma
  • +3 more
  • Lenvatinib Mesylate
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 5, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Beijing (HS-20089)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Beijing, Beijing, China
    Lingying Wu
Aug 22, 2023

DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

Not yet recruiting
  • Endometrial Cancer
  • (no location specified)
Feb 14, 2023

Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)

Not yet recruiting
  • Ovarian Cancer
  • Malignant Neoplasm of Uterus
  • New York, New York
    Icahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023

Endometrioid Endometrial Cancer Trial (Narazaciclib, Letrozole 2.5mg)

Not yet recruiting
  • Endometrioid Endometrial Cancer
  • (no location specified)
Feb 1, 2023

Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • +8 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +7 more
  • (no location specified)
Jul 15, 2023

Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma Trial (Biopsy, Biospecimen

Not yet recruiting
  • Metastatic Endometrial Carcinoma
  • +7 more
  • Biopsy
  • +5 more
  • (no location specified)
Jan 18, 2023

Endometrial Cancer Trial (Anlotinib + Camrelizumab)

Not yet recruiting
  • Endometrial Cancer
  • Anlotinib + Camrelizumab
  • (no location specified)
Sep 26, 2022

Endometrial Cancer Trial in Birmingham, Saint Louis, Oklahoma City (Bevacizumab, Atezolizumab)

Active, not recruiting
  • Endometrial Cancer
  • Birmingham, Alabama
  • +2 more
Nov 21, 2022

Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)

Completed
  • Endometrial Cancer
  • +4 more
  • Basking Ridge, New Jersey
  • +6 more
Jan 3, 2023

Endometrial Cancer Recurrent Trial in Tainan (Crizotinib 250 MG)

Recruiting
  • Endometrial Cancer Recurrent
  • Crizotinib 250 MG
  • Tainan, Taiwan
    National Cheng Kung University Hospital
Jun 6, 2022

Ovarian Cancer, Endometrial Cancer, Cervix Cancer Trial in Oklahoma City (SHetA2)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
Jul 7, 2022